Automera

Automera is an early-stage company focused on developing a novel therapeutic approach based on autophagy-mediated targeted protein degradation. Automera aims to leverage its unique understanding of autophagy, drug development capabilities, and insights into quantum chemistry and generative artificial intelligence to enhance its drug development programs. The AUTAC platform from Automera holds broad potential in the fields of oncology and other diseases, with oncology being the initial lead program.